West Pharmaceutical Services WST Equity Method Income
Equity Method Income at other companies
Other financials
Where this comes from
Reported directly by West Pharmaceutical Services in its filing.
Tagged under the XBRL concept us-gaap:IncomeLossFromEquityMethodInvestments.
The official record: West Pharmaceutical Services’s 10-Q, filed April 23, 2026, on SEC EDGAR. View the filing →
Ask your AI about West Pharmaceutical Services's equity method income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is West Pharmaceutical Services's equity method income?
- West Pharmaceutical Services (WST) reported equity method income of $3.4M in Q1 2026.
- How has West Pharmaceutical Services's equity method income changed year-over-year?
- West Pharmaceutical Services's equity method income decreased by 0.0% year-over-year, from $3.4M to $3.4M.
- What is the long-term trend for West Pharmaceutical Services's equity method income?
- Over 4 years (2021 to 2025), West Pharmaceutical Services's equity method income has grown at a -8.0% compound annual growth rate (CAGR), from $20.1M to $14.4M.
- What does equity method income mean?
- The company's proportional share of net income or loss from unconsolidated affiliates and joint ventures accounted for under the equity method.